**Table S3. The clinical characteristics of HCC patients in each dataset**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Dataset  Characteristic | TCGA[1,2] | MSK, Clin Cancer Res 2018[3] | INSERM, Nat Genet 2015[4] | AMC, Hepatology 2014[5] |
| TIMER2.0 | √ | - | - | - |
| UALCAN | √ | - | - | - |
| cBioPortal | √ | √ | √ | √ |
| Kaplan-Meier plotter | √ | - | - | - |
| GEPIA | √ | - | - | - |
|  |  |  |  |  |
| samples | n=372 | n=127 | n=243 | n=231 |
| Sex |  |  |  |  |
| Male | n=251 | n=99 | n=195 | - |
| Female | n=121 | n=28 | n=48 | - |
| Sample Types |  |  |  |  |
| Primary | - | n=107 | - | - |
| Metastasis | - | n=16 | - | - |
| Local Recurrence | - | n=2 | - | - |
| Tumor Type |  |  |  |  |
| Hepatocellular Carcinoma | n=362 | - | - | - |
| Hepatocholangiocarcinoma (Mixed) | n=7 | - | - | - |
| Fibrolamellar Carcinoma | n=3 | - | - | - |
| Vascular invasion |  |  |  |  |
| None | n=205 | - | n=108 | - |
| Micro | n=93 | - | n=128 | - |
| Macro | n=16 | - | - |
| BCLC stage |  |  |  |  |
| 0\_A | - | - | n=160 | - |
| B\_C | - | - | n=74 | - |
| NA | - | - | n=9 | - |
| AJCC\_T |  |  |  |  |
| I | n=181 | - | - | - |
| II | n=94 | - | - | - |
| III | n=80 | - | - | - |
| IV | n=13 | - | - | - |
| Stage |  |  |  |  |
| I | n=171 | - | - | - |
| II | n=86 | - | - | - |
| III | n=85 | - | - | - |
| IV | n=5 | - | - | - |
| Grade |  |  |  |  |
| I | n=55 | - | - | - |
| II | n=177 | - | - | - |
| III | n=122 | - | - | - |
| IV | n=12 | - | - | - |
| Etiology |  |  |  |  |
| Al | - | - | n=57 | - |
| HCV | - | - | n=46 | - |
| HBV | - | - | n=26 | - |
| W/O Etiology | - | - | n=25 | - |
| METAB | - | - | n=20 | - |
| Al. METAB | - | - | n=19 | - |
| Al. HCV | - | - | n=13 | - |
| HM | - | - | n=11 | - |
| OTHER | - | - | n=10 | - |
| Al. HBV | - | - | n=4 | - |
| Al. HBV HCV | - | - | n=4 | - |
| Al. HM | - | - | n=3 | - |
| HCV METAB | - | - | n=2 | - |
| HM METAB | - | - | n=2 | - |
| Al. HBV METAB | - | - | n=1 | - |
| Cirrhosis |  |  |  |  |
| I | - | - | - | n=20 |
| II | - | - | - | n=26 |
| III | - | - | - | n=72 |
| IV | - | - | - | n=113 |
| Neoplasm Histologic Grade |  |  |  |  |
| I | - | - | - | n=2 |
| II | - | - | - | n=79 |
| III | - | - | - | n=113 |
| IV | - | - | - | n=19 |
| IIII | - | - | - | n=18 |

TCGA, The Cancer Genome Atlas.

**References**

[1] [Ally](https://pubmed.ncbi.nlm.nih.gov/?term=Ally+A) A, [Balasundaram](https://pubmed.ncbi.nlm.nih.gov/?term=Balasundaram+M) M, [Carlsen](https://pubmed.ncbi.nlm.nih.gov/?term=Carlsen+R) R, [Chuah](https://pubmed.ncbi.nlm.nih.gov/?term=Chuah+E) E, [Clarke](https://pubmed.ncbi.nlm.nih.gov/?term=Clarke+A) A, [Dhalla](https://pubmed.ncbi.nlm.nih.gov/?term=Dhalla+N) N, *et al*. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327-41.

[2] Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. [Royal Society Open Science](https://sci.justscience.cn/details.html?sci=1&id=12204). 2018;5(12):181006.

[3] Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, *et al*. Prospective genotyping of hepatocellular carcinoma: Clinical implications of Next-Generation sequencing for matching patients to targeted and immune therapies. Clinical Cancer Research. 2019;25(7):2116-26.

[4] Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, *et al*. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics. 2015;47(5):505-11.

[5] Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, *et al*. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60(6):1972-82.